SCHEMBL7200528

SCHEMBL7200528

Sc1nc(-c2ccc(Cl)cc2)n[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.56
NR1H3 Q13133 2/20 0.56
RET P07949 2/20 0.50
EGFR P00533 1/20 0.50
KDR P35968 1/20 0.50
S1PR1 P21453 1/20 0.46
S1PR3 Q99500 1/20 0.46
RPA1 P27694 1/20 0.46
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
ALPL P05186 2/20 0.43
ROCK2 O75116 3/20 0.42
GRK2 P25098 2/20 0.42
NOTUM Q6P988 2/20 0.42
DCUN1D1 Q96GG9 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
METAP2 P50579 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657644 0.79 NR1H2 (0.61) NR1H2NR1H3S1PR1S1PR3RAB9A
SCHEMBL11187134 0.78 NR1H2 (0.86) NR1H2NR1H3RETEGFRKDR
SCHEMBL4865340 0.78 JAK2 (0.49) ROCK2GRK2
SCHEMBL4859334 0.76 NR1H2 (0.56) NR1H2NR1H3RETEGFRKDR
SCHEMBL1528410 0.76 NR1H2 (0.56) NR1H2NR1H3RETEGFRKDR
SCHEMBL2485799 0.76 XDH (0.49) NR1H2NR1H3S1PR1RAB9ANPC1
SCHEMBL9253965 0.74 NOTUM (0.45) NOTUMCA12CA1CA2CA9
SCHEMBL27482226 0.73 NR1H2 (0.53) NR1H2NR1H3RETEGFRKDR
SCHEMBL12686395 0.73 XDH (0.53) RAB9ANPC1NOTUM
SCHEMBL29035842 0.72 NR1H2 (1.00) NR1H2NR1H3S1PR1S1PR3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO NR1H2 4073/4885NR1H3 4221/4885RET 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.